Cipro Buyers, Generics Cos. Duel Over Actavis Ruling

Law360, New York (January 29, 2014, 6:34 PM EST) -- Several generic-drug makers and a group of purchasers suing them over so-called pay-for-delay patent settlements related to Cipro offered dueling interpretations of the U.S. Supreme Court's recent Actavis decision Friday as the plaintiffs try to persuade California's highest court to revive the antitrust case.

The California Supreme Court is weighing an appeal from the would-be class members in the case, who claim they were overcharged for the blockbuster antibiotic because of nearly $400 million Bayer Corp. paid Barr Laboratories Inc., Hoechst Marion Roussel Inc., The Rugby...
To view the full article, register now.